证券代码：688180 证券简称：君实生物 公告编号：临 2025-053 公司监事会核查了本次激励计划拟首次授予激励对象的名单、身份证件、拟 首次授予激励对象与公司（含子公司）签订的劳动合同/劳务合同、拟首次授予 激励对象在公司（含子公司）担任的职务等。 一、公示情况及核查方式 （一）公示情况 公司于 2025 年 9 月 3 日在上海证券交易所网站（www.sse.com.cn）上披露 了《上海君实生物医药科技股份有限公司 2025 年 A 股股票期权激励计划（草案）》 （以下简称"《激励计划（草案）》"）及其摘要、《上海君实生物医药科技股 份有限公司 2025 年 A 股股票期权激励计划首次授予激励对象名单》等文件。 公司于 2025 年 9 月 3 日至 2025 年 9 月 13 日在公司内部对本次激励计划拟 首次授予部分激励对象的姓名和职务进行了公示，公示期共计 10 天，公司员工 可向公司监事会提出意见。 截至公示期满，公司监事会未收到任何人对本次激励计划拟首次授予激励对 象提出的异议。 （二）关于公司监事会对拟激励对象的核查方式 上海君实生物医药科技股份有限公司监事会 关于公司 2025 年 ...

Core Viewpoint - Junshi Biosciences (688180.SH) reported a significant increase in revenue for the first half of 2025, achieving 1.168 billion yuan, a year-on-year growth of 48.64%, while still facing net losses [1][3]. Financial Performance - The company's operating revenue for H1 2025 was 1.168 billion yuan, up from 0.785 billion yuan in the same period last year, reflecting a growth of 48.64% [1][3]. - The net profit attributable to shareholders was -413 million yuan, an improvement from -645 million yuan in the previous year [1][3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -478 million yuan, compared to -627 million yuan in the same period last year [1][3]. - The net cash flow from operating activities was -329 million yuan, an improvement from -865 million yuan year-on-year [1][3]. Historical Financial Data - From 2016 to 2024, the net profit attributable to shareholders showed a consistent trend of losses, with figures ranging from -135 million yuan to -2.388 billion yuan [3]. - The net profit after deducting non-recurring gains and losses also reflected similar losses, ranging from -160 million yuan to -2.490 billion yuan during the same period [3]. Capital Raising Activities - Junshi Biosciences was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on July 15, 2020, raising a total of 4.836 billion yuan, with a net amount of 4.497 billion yuan after expenses [4]. - The company planned to use the raised funds for innovative drug research and development, industrialization projects, repaying bank loans, and supplementing working capital [4]. - In 2022, the company raised an additional 3.776 billion yuan through a private placement of shares, with a net amount of approximately 3.745 billion yuan after expenses [5].

Group 1 - On September 19, Junshi Biosciences-U executed a block trade of 1 million shares, amounting to 43.69 million yuan, with a transaction price of 43.69 yuan, reflecting a discount of 0.70% compared to the closing price of the day [2] - In the past three months, Junshi Biosciences-U has recorded a total of 11 block trades, with a cumulative transaction amount of 515 million yuan [2] - The closing price of Junshi Biosciences-U on the same day was 44.00 yuan, showing a decline of 3.78%, with a turnover rate of 2.48% and a total trading volume of 847 million yuan, indicating a net outflow of 114 million yuan in main funds for the day [2] Group 2 - Over the past five days, Junshi Biosciences-U has experienced a cumulative decline of 9.84%, with a total net outflow of funds amounting to 297 million yuan [2] - The latest margin financing balance for Junshi Biosciences-U is 1.422 billion yuan, which has increased by 78.759 million yuan over the past five days, representing a growth rate of 5.86% [2]

Group 1 - The top three companies with the highest short position ratios are ZTE Corporation (00763) at 15.37%, COSCO Shipping Holdings (01919) at 14.41%, and CATL (03750) at 13.38% [1][2] - The company with the largest increase in short position ratio is China Pacific Insurance (02601), which rose by 5.56% to 7.72% [2] - The companies with the largest decrease in short position ratio include Shandong Gold (01787), which decreased by 3.98% to 8.68%, and Kingsoft Cloud (03896), which decreased by 1.65% to 2.96% [1][3] Group 2 - The latest short position ratios for the top ten companies show that Zijin Mining (02899) has a ratio of 13.12%, Ping An Insurance (02318) at 12.68%, and MicroPort Medical (00853) at 11.92% [2] - The companies with the most significant increases in short position ratios also include Hengrui Medicine (01276) with an increase of 0.98% to 8.19% and Kanglong Chemical (03759) with an increase of 0.93% to 7.27% [2] - The companies with the most significant decreases in short position ratios also include Kangfang Biotech (09926) with a decrease of 1.02% to 3.89% and Shengye (06069) with a decrease of 0.99% to 1.83% [3]

Group 1 - The Hong Kong innovative drug sector experienced a decline in the afternoon session on September 13, with notable drops in stock prices [1] - Innovent Biologics saw a decrease of over 7%, while Rongchang Biopharmaceutical and Green Leaf Pharmaceutical fell by more than 4% [1] - Other companies such as WuXi Biologics, Junshi Biosciences, and Kelun Pharmaceutical also experienced declines [1]

Company Overview - Junshi Biosciences is located in Shanghai and specializes in the research and commercialization of monoclonal antibody drugs and other therapeutic protein drugs, with main business revenue comprising 90.67% from drug sales, 8.74% from technology licensing, and 0.59% from technical services and others [2] Financial Performance - For the first half of 2025, Junshi Biosciences achieved a revenue of 1.168 billion yuan, representing a year-on-year growth of 48.64%, while the net profit attributable to shareholders was -413 million yuan, showing a year-on-year increase of 36.01% [2] Shareholder Structure - As of June 30, 2025, the number of shareholders of Junshi Biosciences increased by 5.88% to 31,200, with an average of 24,543 circulating shares per person, a decrease of 5.56% from the previous period [2] Market Activity - On September 18, Junshi Biosciences saw a trading volume of 909 million yuan, with a net financing purchase of 19.83 million yuan, indicating strong market interest [1] - The financing balance reached 1.422 billion yuan, accounting for 4.06% of the circulating market value, which is above the 90th percentile of the past year, indicating a high level of financing activity [1] Institutional Holdings - As of June 30, 2025, major institutional shareholders include Huaxia SSE STAR 50 ETF and E Fund SSE STAR 50 ETF, with changes in their holdings reflecting varying levels of institutional interest [3]

两融数据显示，该股最新融资余额为14.03亿元，近5日增加5311.18万元，增幅为3.94%。（数据宝） 进一步统计，近3个月内该股累计发生10笔大宗交易，合计成交金额为4.71亿元。 注：本文系新闻报道，不构成投资建议，股市有风险，投资需谨慎。 证券时报·数据宝统计显示，君实生物-U今日收盘价为45.73元，上涨0.20%，日换手率为2.57%，成交额为9.09亿元，全天主力资金净流出3762.49万元，近5日该股累计下跌4.19%，近5日 君实生物-U9月18日大宗交易平台出现一笔成交，成交量100.00万股，成交金额4541.00万元，大宗交易成交价为45.41元，相对今日收盘价折价0.70%。该笔交易的买方营业部为方正证券股 9月18日君实生物-U大宗交易一览 ...

两融数据显示，该股最新融资余额为14.03亿元，近5日增加5311.18万元，增幅为3.94%。（数据宝） 9月18日君实生物-U大宗交易一览 君实生物-U9月18日大宗交易平台出现一笔成交，成交量100.00万股，成交金额4541.00万元，大宗交易 成交价为45.41元，相对今日收盘价折价0.70%。该笔交易的买方营业部为方正证券股份有限公司总部， 卖方营业部为中信证券股份有限公司上海浦东新区东方路证券营业部。 进一步统计，近3个月内该股累计发生10笔大宗交易，合计成交金额为4.71亿元。 证券时报·数据宝统计显示，君实生物-U今日收盘价为45.73元，上涨0.20%，日换手率为2.57%，成交额 为9.09亿元，全天主力资金净流出3762.49万元，近5日该股累计下跌4.19%，近5日资金合计净流出1.71 亿元。 | 成交量 （万 | 成交金额 | 成交价 | 相对当日收盘折 | 买方营业部 | | | --- | --- | --- | --- | --- | --- | | | （万元） | 格 | 溢价（%） | | 卖方营业部 | | 股） | | （元） | | | | | 100.00 | ...

炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 9月18日，君实生物收涨0.20%，收盘价为45.73元，发生1笔大宗交易，合计成交量100万股，成交金额 4541万元。 进一步统计，近3个月内该股累计发生10笔大宗交易，合计成交金额为4.71亿元。该股近5个交易日累计 下跌4.19%，主力资金合计净流出1.75亿元。 责任编辑：小浪快报 第1笔成交价格为45.41元，成交100.00万股，成交金额4,541.00万元，溢价率为-0.70%，买方营业部为方 正证券股份有限公司总部，卖方营业部为中信证券股份有限公司上海浦东新区东方路证券营业部。 ...

Core Viewpoint - Junshi Biosciences aims to establish itself as a global innovative pharmaceutical company with a complete industry chain capability from drug discovery to commercialization, focusing on quality and innovation [2][3]. Company Overview - Junshi Biosciences, founded on December 27, 2012, and listed on July 15, 2020, specializes in the research and commercialization of monoclonal antibody drugs and other therapeutic proteins [7]. - The company's main revenue sources include drug sales (90.67%), technology licensing (8.74%), and other services (0.59%) [7]. Product Development - The company has developed a promising drug portfolio, including its core product, Toripalimab, which is the first domestically approved PD-1 monoclonal antibody in China, with 11 approved indications and one supplemental NDA under review [2]. - Toripalimab is also the first innovative biologic drug developed and produced in China to receive FDA approval, with approvals in multiple regions including the U.S., EU, and Australia [2]. - Junshi is advancing its pipeline with Tifcemalimab, the first anti-BTLA monoclonal antibody entering clinical development, currently undergoing two Phase III trials [2]. Vaccine Development - The company is collaborating with various research institutions to develop vaccines, including monkeypox and Zika vaccines, which are currently in preclinical development [3]. - A partnership with Peking University and other institutions has been established to jointly develop a recombinant protein vaccine for monkeypox [3]. Financial Performance - For the first half of 2025, Junshi Biosciences reported revenue of 1.168 billion yuan, a year-on-year increase of 48.64%, while the net profit attributable to shareholders was -413 million yuan, reflecting a 36.01% increase [8]. - As of June 30, 2025, the number of shareholders increased by 5.88% to 31,200, with a decrease in average circulating shares per person by 5.56% [8]. Market Activity - On September 18, the stock price of Junshi Biosciences increased by 0.20%, with a trading volume of 909 million yuan and a turnover rate of 2.57%, resulting in a total market capitalization of 46.951 billion yuan [1]. - Recent trading activity indicates a net outflow of 31.6178 million yuan from main funds, with a lack of clear trends in main fund movements [4][5].